Tianjin Tianyao Pharmaceuticals Co Ltd (600488) - Net Assets

Latest as of September 2025: CN¥3.89 Billion CNY ≈ $569.86 Million USD

Based on the latest financial reports, Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has net assets worth CN¥3.89 Billion CNY (≈ $569.86 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.74 Billion ≈ $840.40 Million USD) and total liabilities (CN¥1.85 Billion ≈ $270.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tianjin Tianyao Pharmaceuticals Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥3.89 Billion
% of Total Assets 67.81%
Annual Growth Rate 15.94%
5-Year Change 3.0%
10-Year Change 58.69%
Growth Volatility 46.64

Tianjin Tianyao Pharmaceuticals Co Ltd - Net Assets Trend (1998–2024)

This chart illustrates how Tianjin Tianyao Pharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Tianjin Tianyao Pharmaceuticals Co Ltd's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Tianjin Tianyao Pharmaceuticals Co Ltd (1998–2024)

The table below shows the annual net assets of Tianjin Tianyao Pharmaceuticals Co Ltd from 1998 to 2024. For live valuation and market cap data, see Tianjin Tianyao Pharmaceuticals Co Ltd market cap and net worth.

Year Net Assets Change
2024-12-31 CN¥3.89 Billion
≈ $568.62 Million		 +3.53%
2023-12-31 CN¥3.75 Billion
≈ $549.23 Million		 -0.01%
2022-12-31 CN¥3.75 Billion
≈ $549.30 Million		 -1.65%
2021-12-31 CN¥3.82 Billion
≈ $558.53 Million		 +1.17%
2020-12-31 CN¥3.77 Billion
≈ $552.05 Million		 +5.20%
2019-12-31 CN¥3.59 Billion
≈ $524.74 Million		 +9.26%
2018-12-31 CN¥3.28 Billion
≈ $480.28 Million		 +4.89%
2017-12-31 CN¥3.13 Billion
≈ $457.91 Million		 +25.65%
2016-12-31 CN¥2.49 Billion
≈ $364.44 Million		 +1.71%
2015-12-31 CN¥2.45 Billion
≈ $358.33 Million		 +2.23%
2014-12-31 CN¥2.40 Billion
≈ $350.53 Million		 +2.99%
2013-12-31 CN¥2.33 Billion
≈ $340.36 Million		 +31.57%
2012-12-31 CN¥1.77 Billion
≈ $258.69 Million		 +4.80%
2011-12-31 CN¥1.69 Billion
≈ $246.84 Million		 +3.39%
2010-12-31 CN¥1.63 Billion
≈ $238.75 Million		 +4.86%
2009-12-31 CN¥1.56 Billion
≈ $227.69 Million		 +3.46%
2008-12-31 CN¥1.50 Billion
≈ $220.07 Million		 +2.96%
2007-12-31 CN¥1.46 Billion
≈ $213.75 Million		 +35.57%
2006-12-31 CN¥1.08 Billion
≈ $157.67 Million		 +3.14%
2005-12-31 CN¥1.04 Billion
≈ $152.86 Million		 +5.79%
2004-12-31 CN¥987.47 Million
≈ $144.50 Million		 +5.54%
2003-12-31 CN¥935.65 Million
≈ $136.92 Million		 +19.27%
2002-12-31 CN¥784.51 Million
≈ $114.80 Million		 +9.78%
2001-12-31 CN¥714.63 Million
≈ $104.57 Million		 +237.49%
2000-12-31 CN¥211.75 Million
≈ $30.99 Million		 +44.87%
1999-12-31 CN¥146.16 Million
≈ $21.39 Million		 +76.10%
1998-12-31 CN¥83.00 Million
≈ $12.15 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Tianjin Tianyao Pharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 128580836000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥1.29 Billion 42.06%
Common Stock CN¥1.09 Billion 35.71%
Other Comprehensive Income CN¥362.28 Million 11.85%
Other Components CN¥317.38 Million 10.38%
Total Equity CN¥3.06 Billion 100.00%

Tianjin Tianyao Pharmaceuticals Co Ltd Competitors by Market Cap

The table below lists competitors of Tianjin Tianyao Pharmaceuticals Co Ltd ranked by their market capitalization.

Company Market Cap
Ategrity Specialty Insurance Company Holdings
NYSE:ASIC
 $943.07 Million
Arena REIT
AU:ARF
 $943.08 Million
Thungela Resources Limited
JSE:TGA
 $943.31 Million
Bumi Serpong Damai Tbk
JK:BSDE
 $943.59 Million
Yuhuan CNC Machine Tool Co Ltd
SHE:002903
 $942.65 Million
Bear Electric Appliance Co Ltd
SHE:002959
 $942.27 Million
Daewon Cable
KO:006340
 $942.27 Million
China Motor Corp
TW:2204
 $941.87 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tianjin Tianyao Pharmaceuticals Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,953,554,191 to 3,057,347,087, a change of 103,792,896 (3.5%).
  • Net income of 133,450,642 contributed positively to equity growth.
  • Dividend payments of 123,370,544 reduced retained earnings.
  • Share repurchases of 4,771,578 reduced equity.
  • Other comprehensive income increased equity by 315,323,362.
  • Other factors decreased equity by 216,838,986.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥133.45 Million +4.36%
Dividends Paid CN¥123.37 Million -4.04%
Share Repurchases CN¥4.77 Million -0.16%
Other Comprehensive Income CN¥315.32 Million +10.31%
Other Changes CN¥-216.84 Million -7.09%
Total Change CN¥- 3.51%

Book Value vs Market Value Analysis

This analysis compares Tianjin Tianyao Pharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.11x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 53.60x to 2.11x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1998-12-31 CN¥0.11 CN¥5.90 x
1999-12-31 CN¥0.19 CN¥5.90 x
2000-12-31 CN¥0.28 CN¥5.90 x
2001-12-31 CN¥0.94 CN¥5.90 x
2002-12-31 CN¥1.01 CN¥5.90 x
2003-12-31 CN¥1.18 CN¥5.90 x
2004-12-31 CN¥1.25 CN¥5.90 x
2005-12-31 CN¥1.32 CN¥5.90 x
2006-12-31 CN¥1.46 CN¥5.90 x
2007-12-31 CN¥1.75 CN¥5.90 x
2008-12-31 CN¥1.81 CN¥5.90 x
2009-12-31 CN¥1.86 CN¥5.90 x
2010-12-31 CN¥1.95 CN¥5.90 x
2011-12-31 CN¥2.05 CN¥5.90 x
2012-12-31 CN¥2.15 CN¥5.90 x
2013-12-31 CN¥2.49 CN¥5.90 x
2014-12-31 CN¥2.47 CN¥5.90 x
2015-12-31 CN¥2.53 CN¥5.90 x
2016-12-31 CN¥2.27 CN¥5.90 x
2017-12-31 CN¥2.49 CN¥5.90 x
2018-12-31 CN¥2.60 CN¥5.90 x
2019-12-31 CN¥2.67 CN¥5.90 x
2020-12-31 CN¥2.74 CN¥5.90 x
2021-12-31 CN¥2.74 CN¥5.90 x
2022-12-31 CN¥2.72 CN¥5.90 x
2023-12-31 CN¥2.71 CN¥5.90 x
2024-12-31 CN¥2.80 CN¥5.90 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tianjin Tianyao Pharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.36%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 4.15%
  • • Asset Turnover: 0.56x
  • • Equity Multiplier: 1.86x
  • Recent ROE (4.36%) is below the historical average (7.66%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1998 14.89% 3.69% 1.15x 3.49x CN¥4.06 Million
1999 36.52% 10.92% 1.19x 2.81x CN¥38.76 Million
2000 30.97% 13.22% 0.99x 2.37x CN¥44.41 Million
2001 10.63% 14.80% 0.45x 1.60x CN¥4.44 Million
2002 11.97% 14.97% 0.43x 1.87x CN¥14.98 Million
2003 10.14% 13.48% 0.42x 1.81x CN¥1.26 Million
2004 10.73% 10.46% 0.63x 1.63x CN¥6.85 Million
2005 8.11% 12.22% 0.33x 1.99x CN¥-18.84 Million
2006 4.28% 7.52% 0.24x 2.36x CN¥-58.79 Million
2007 1.83% 3.74% 0.30x 1.62x CN¥-116.83 Million
2008 3.42% 5.73% 0.34x 1.75x CN¥-96.63 Million
2009 4.31% 7.37% 0.34x 1.73x CN¥-86.38 Million
2010 5.71% 8.05% 0.39x 1.83x CN¥-68.30 Million
2011 5.59% 6.57% 0.59x 1.45x CN¥-73.44 Million
2012 5.66% 6.02% 0.66x 1.43x CN¥-75.89 Million
2013 2.25% 3.51% 0.48x 1.35x CN¥-178.61 Million
2014 3.65% 6.23% 0.48x 1.22x CN¥-150.89 Million
2015 3.24% 5.60% 0.46x 1.25x CN¥-164.07 Million
2016 2.58% 5.29% 0.40x 1.22x CN¥-183.15 Million
2017 4.77% 6.58% 0.46x 1.58x CN¥-142.07 Million
2018 5.41% 6.32% 0.51x 1.69x CN¥-130.35 Million
2019 4.98% 4.98% 0.55x 1.81x CN¥-146.72 Million
2020 2.69% 2.59% 0.50x 2.06x CN¥-218.58 Million
2021 3.63% 2.90% 0.59x 2.12x CN¥-190.63 Million
2022 0.62% 0.50% 0.55x 2.24x CN¥-278.81 Million
2023 3.96% 3.09% 0.62x 2.08x CN¥-178.30 Million
2024 4.36% 4.15% 0.56x 1.86x CN¥-172.28 Million

Industry Comparison

This section compares Tianjin Tianyao Pharmaceuticals Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $4,691,234,838
  • Average return on equity (ROE) among peers: 6.16%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tianjin Tianyao Pharmaceuticals Co Ltd (600488) CN¥3.89 Billion 14.89% 0.47x $942.69 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $903.62 Million 4.28% 2.45x $1.16 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.22 Billion 5.35% 1.27x $441.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $9.87 Billion 20.71% 0.25x $5.01 Billion
Livzon Pharmaceutical Group Inc (000513) $1.07 Billion 3.83% 0.46x $2.80 Billion
Wedge Industrial Co Ltd (000534) $1.15 Billion 11.42% 1.59x $3.04 Billion
Yunnan Baiyao Group Co Ltd (000538) $9.03 Billion 25.71% 0.43x $13.75 Billion
Hainan Haiyao Co Ltd (000566) $275.57 Million 17.28% 1.12x $947.33 Million
Tus Pharmaceutical Group Co Ltd (000590) $231.22 Million -38.13% 1.23x $389.67 Million
Northeast Pharmaceutical Group Co Ltd (000597) $4.29 Billion 2.31% 2.07x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $18.87 Billion 8.83% 0.08x $3.32 Billion

About Tianjin Tianyao Pharmaceuticals Co Ltd

SHG:600488 China Drug Manufacturers - Specialty & Generic
Market Cap
$942.69 Million
CN¥6.44 Billion CNY
Market Cap Rank
#9425 Global
#2587 in China
Share Price
CN¥5.90
Change (1 day)
+3.51%
52-Week Range
CN¥3.71 - CN¥7.67
All Time High
CN¥7.67
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more